PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32637030-0	2020	RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit.	BI D1870	14-22	ribosomal protein S6 kinase A2	Homo sapiens	0-3
19765648-8	2009	While BI-D1870 partially inhibited insulin-stimulated PKB activation in these cells, this only partially inhibited AS160 phosphorylation and did not block GLUT4 trafficking, suggesting that p90RSK might regulate glucose transport after GLUT4 translocation.	BI D1870	6-14	insulin	Homo sapiens	35-42
19332537-6	2009	RSK-dependent Ser-260 phosphorylation was sensitive to the MEK inhibitor UO126 and the RSK inhibitor BID-1870.	BI D1870	101-109	ribosomal protein S6 kinase A2	Homo sapiens	0-3
19332537-6	2009	RSK-dependent Ser-260 phosphorylation was sensitive to the MEK inhibitor UO126 and the RSK inhibitor BID-1870.	BI D1870	101-109	ribosomal protein S6 kinase A2	Homo sapiens	87-90
17617058-8	2007	In cells, the IGF-1-stimulated phosphorylations, and certain EGF-stimulated phosphorylations, were inhibited by PI3K (phosphoinositide 3-kinase) inhibitors, whereas the RSK inhibitor BI-D1870 inhibited the PMA-induced phosphorylations.	BI D1870	183-191	insulin like growth factor 1	Homo sapiens	14-19
17617058-8	2007	In cells, the IGF-1-stimulated phosphorylations, and certain EGF-stimulated phosphorylations, were inhibited by PI3K (phosphoinositide 3-kinase) inhibitors, whereas the RSK inhibitor BI-D1870 inhibited the PMA-induced phosphorylations.	BI D1870	183-191	epidermal growth factor	Homo sapiens	61-64
17040210-0	2007	BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo.	BI D1870	0-8	ribosomal protein S6 kinase A1	Homo sapiens	40-47
17040210-0	2007	BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo.	BI D1870	0-8	ribosomal protein S6 kinase A1	Homo sapiens	49-68
34602526-4	2021	BI-D1870, a potent inhibitor of RSK, significantly suppressed the proliferation of AML cell lines, among which three encoded wild-type FLT3 and three contained FLT3 driver mutations, compared with chronic myeloid leukemia K562 cells or other adherent cancer cells.	BI D1870	0-8	ribosomal protein S6 kinase A2	Homo sapiens	32-35
34602526-4	2021	BI-D1870, a potent inhibitor of RSK, significantly suppressed the proliferation of AML cell lines, among which three encoded wild-type FLT3 and three contained FLT3 driver mutations, compared with chronic myeloid leukemia K562 cells or other adherent cancer cells.	BI D1870	0-8	fms related receptor tyrosine kinase 3	Homo sapiens	135-139
34602526-4	2021	BI-D1870, a potent inhibitor of RSK, significantly suppressed the proliferation of AML cell lines, among which three encoded wild-type FLT3 and three contained FLT3 driver mutations, compared with chronic myeloid leukemia K562 cells or other adherent cancer cells.	BI D1870	0-8	fms related receptor tyrosine kinase 3	Homo sapiens	160-164
34602526-10	2021	The findings suggested that BI-D1870 alone exerts an adequate antiproliferative effect on AML with or without FLT3 mutations and serves as a novel AML therapeutic agent.	BI D1870	28-36	fms related receptor tyrosine kinase 3	Homo sapiens	110-114
32420699-5	2020	Comparative gene expression profiling of the MCL-derived cell lines showed that inhibition of RSK2Ser227 by BI-D1870 caused downregulation of oncogenes, such as c-MYC and MYB; anti-apoptosis genes, such as BCL2 and BCL2L1; genes for B cell development, including IKZF1, IKZF3, and PAX5; and genes constituting the B cell receptor signaling pathway, such as CD19, CD79B, and BLNK.	BI D1870	108-116	paired box 5	Homo sapiens	281-285
32420699-5	2020	Comparative gene expression profiling of the MCL-derived cell lines showed that inhibition of RSK2Ser227 by BI-D1870 caused downregulation of oncogenes, such as c-MYC and MYB; anti-apoptosis genes, such as BCL2 and BCL2L1; genes for B cell development, including IKZF1, IKZF3, and PAX5; and genes constituting the B cell receptor signaling pathway, such as CD19, CD79B, and BLNK.	BI D1870	108-116	CD19 molecule	Homo sapiens	357-361
32420699-5	2020	Comparative gene expression profiling of the MCL-derived cell lines showed that inhibition of RSK2Ser227 by BI-D1870 caused downregulation of oncogenes, such as c-MYC and MYB; anti-apoptosis genes, such as BCL2 and BCL2L1; genes for B cell development, including IKZF1, IKZF3, and PAX5; and genes constituting the B cell receptor signaling pathway, such as CD19, CD79B, and BLNK.	BI D1870	108-116	CD79b molecule	Homo sapiens	363-368
32420699-5	2020	Comparative gene expression profiling of the MCL-derived cell lines showed that inhibition of RSK2Ser227 by BI-D1870 caused downregulation of oncogenes, such as c-MYC and MYB; anti-apoptosis genes, such as BCL2 and BCL2L1; genes for B cell development, including IKZF1, IKZF3, and PAX5; and genes constituting the B cell receptor signaling pathway, such as CD19, CD79B, and BLNK.	BI D1870	108-116	B cell linker	Homo sapiens	374-378
32420699-7	2020	In addition, we found favorable combinatory growth inhibitory effects of BI-D1870 with inhibitors of BTK (ibrutinib), AKT (ipatasertib), and BCL2 (venetoclax) in cell characteristic-dependent manners.	BI D1870	73-81	Bruton tyrosine kinase	Homo sapiens	101-104
32420699-7	2020	In addition, we found favorable combinatory growth inhibitory effects of BI-D1870 with inhibitors of BTK (ibrutinib), AKT (ipatasertib), and BCL2 (venetoclax) in cell characteristic-dependent manners.	BI D1870	73-81	AKT serine/threonine kinase 1	Homo sapiens	118-121
32420699-7	2020	In addition, we found favorable combinatory growth inhibitory effects of BI-D1870 with inhibitors of BTK (ibrutinib), AKT (ipatasertib), and BCL2 (venetoclax) in cell characteristic-dependent manners.	BI D1870	73-81	BCL2 apoptosis regulator	Homo sapiens	141-145
34089554-12	2021	BI-D1870, a specific RSK inhibitor, partly prevented PTTH-stimulated RSK phosphorylation and significantly inhibited PTTH-stimulated ecdysteroid secretion, indicating that PTTH-stimulated RSK phosphorylation is involved in ecdysteroidogenesis.	BI D1870	0-8	prothoracicotropic hormone	Bombyx mori	53-57
34089554-12	2021	BI-D1870, a specific RSK inhibitor, partly prevented PTTH-stimulated RSK phosphorylation and significantly inhibited PTTH-stimulated ecdysteroid secretion, indicating that PTTH-stimulated RSK phosphorylation is involved in ecdysteroidogenesis.	BI D1870	0-8	prothoracicotropic hormone	Bombyx mori	117-121
34089554-12	2021	BI-D1870, a specific RSK inhibitor, partly prevented PTTH-stimulated RSK phosphorylation and significantly inhibited PTTH-stimulated ecdysteroid secretion, indicating that PTTH-stimulated RSK phosphorylation is involved in ecdysteroidogenesis.	BI D1870	0-8	prothoracicotropic hormone	Bombyx mori	172-176
35328342-4	2022	The combinatory treatment of BI-D1870, an inhibitor for N-terminal kinase domain (NTKD) of RSK2, and ipatasertib, an inhibitor for AKT, showed the additive to synergistic anti-tumor effect on human MM-derived cell lines (HMCLs) with active RSK2-NTKD and AKT, by enhancing apoptotic induction with BIM and BID activation.	BI D1870	29-37	ribosomal protein S6 kinase A3	Homo sapiens	91-95
35328342-4	2022	The combinatory treatment of BI-D1870, an inhibitor for N-terminal kinase domain (NTKD) of RSK2, and ipatasertib, an inhibitor for AKT, showed the additive to synergistic anti-tumor effect on human MM-derived cell lines (HMCLs) with active RSK2-NTKD and AKT, by enhancing apoptotic induction with BIM and BID activation.	BI D1870	29-37	ribosomal protein S6 kinase A3	Homo sapiens	240-244
35328342-4	2022	The combinatory treatment of BI-D1870, an inhibitor for N-terminal kinase domain (NTKD) of RSK2, and ipatasertib, an inhibitor for AKT, showed the additive to synergistic anti-tumor effect on human MM-derived cell lines (HMCLs) with active RSK2-NTKD and AKT, by enhancing apoptotic induction with BIM and BID activation.	BI D1870	29-37	AKT serine/threonine kinase 1	Homo sapiens	254-257
35328342-4	2022	The combinatory treatment of BI-D1870, an inhibitor for N-terminal kinase domain (NTKD) of RSK2, and ipatasertib, an inhibitor for AKT, showed the additive to synergistic anti-tumor effect on human MM-derived cell lines (HMCLs) with active RSK2-NTKD and AKT, by enhancing apoptotic induction with BIM and BID activation.	BI D1870	29-37	BH3 interacting domain death agonist	Homo sapiens	305-308
32667058-6	2020	METHODS: Our study examined the effect of cisplatin, BI-D1870 (RSK inhibitor) or their combination on cell migration, apoptosis, autophagy and cell cycle in A549 human lung adenocarcinoma cells.	BI D1870	53-61	ribosomal protein S6 kinase A3	Homo sapiens	63-66
32667058-7	2020	RESULTS: The combination of cisplatin and BI-D1870 potentiated the antimigration rate, the activation of caspases-3 and was associated with a significant decrease in RSK1 and ERK expression when compared to cisplatin alone.	BI D1870	42-50	ribosomal protein S6 kinase A1	Homo sapiens	166-170
32667058-7	2020	RESULTS: The combination of cisplatin and BI-D1870 potentiated the antimigration rate, the activation of caspases-3 and was associated with a significant decrease in RSK1 and ERK expression when compared to cisplatin alone.	BI D1870	42-50	mitogen-activated protein kinase 1	Homo sapiens	175-178
32420699-3	2020	BI-D1870, an inhibitor specific to RSK2-NTKD, caused RSK2Ser227 dephosphorylation, and thereby, induced dose-dependent growth inhibition via G2 /M cell cycle blockade and apoptosis in four of the five cell lines, while one cell line showed only modest sensitivity.	BI D1870	0-8	ribosomal protein S6 kinase A3	Homo sapiens	35-39
32420699-4	2020	In addition, RSK2 gene knockdown caused growth inhibition in the four BI-D1870-sensitive cell lines.	BI D1870	70-78	ribosomal protein S6 kinase A3	Homo sapiens	13-17
32420699-5	2020	Comparative gene expression profiling of the MCL-derived cell lines showed that inhibition of RSK2Ser227 by BI-D1870 caused downregulation of oncogenes, such as c-MYC and MYB; anti-apoptosis genes, such as BCL2 and BCL2L1; genes for B cell development, including IKZF1, IKZF3, and PAX5; and genes constituting the B cell receptor signaling pathway, such as CD19, CD79B, and BLNK.	BI D1870	108-116	ribosomal protein S6 kinase A3	Homo sapiens	94-98
32420699-5	2020	Comparative gene expression profiling of the MCL-derived cell lines showed that inhibition of RSK2Ser227 by BI-D1870 caused downregulation of oncogenes, such as c-MYC and MYB; anti-apoptosis genes, such as BCL2 and BCL2L1; genes for B cell development, including IKZF1, IKZF3, and PAX5; and genes constituting the B cell receptor signaling pathway, such as CD19, CD79B, and BLNK.	BI D1870	108-116	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	163-166
32420699-5	2020	Comparative gene expression profiling of the MCL-derived cell lines showed that inhibition of RSK2Ser227 by BI-D1870 caused downregulation of oncogenes, such as c-MYC and MYB; anti-apoptosis genes, such as BCL2 and BCL2L1; genes for B cell development, including IKZF1, IKZF3, and PAX5; and genes constituting the B cell receptor signaling pathway, such as CD19, CD79B, and BLNK.	BI D1870	108-116	MYB proto-oncogene, transcription factor	Homo sapiens	171-174
32420699-5	2020	Comparative gene expression profiling of the MCL-derived cell lines showed that inhibition of RSK2Ser227 by BI-D1870 caused downregulation of oncogenes, such as c-MYC and MYB; anti-apoptosis genes, such as BCL2 and BCL2L1; genes for B cell development, including IKZF1, IKZF3, and PAX5; and genes constituting the B cell receptor signaling pathway, such as CD19, CD79B, and BLNK.	BI D1870	108-116	BCL2 apoptosis regulator	Homo sapiens	206-210
32420699-5	2020	Comparative gene expression profiling of the MCL-derived cell lines showed that inhibition of RSK2Ser227 by BI-D1870 caused downregulation of oncogenes, such as c-MYC and MYB; anti-apoptosis genes, such as BCL2 and BCL2L1; genes for B cell development, including IKZF1, IKZF3, and PAX5; and genes constituting the B cell receptor signaling pathway, such as CD19, CD79B, and BLNK.	BI D1870	108-116	BCL2 like 1	Homo sapiens	215-221
32420699-5	2020	Comparative gene expression profiling of the MCL-derived cell lines showed that inhibition of RSK2Ser227 by BI-D1870 caused downregulation of oncogenes, such as c-MYC and MYB; anti-apoptosis genes, such as BCL2 and BCL2L1; genes for B cell development, including IKZF1, IKZF3, and PAX5; and genes constituting the B cell receptor signaling pathway, such as CD19, CD79B, and BLNK.	BI D1870	108-116	IKAROS family zinc finger 1	Homo sapiens	263-268
32420699-5	2020	Comparative gene expression profiling of the MCL-derived cell lines showed that inhibition of RSK2Ser227 by BI-D1870 caused downregulation of oncogenes, such as c-MYC and MYB; anti-apoptosis genes, such as BCL2 and BCL2L1; genes for B cell development, including IKZF1, IKZF3, and PAX5; and genes constituting the B cell receptor signaling pathway, such as CD19, CD79B, and BLNK.	BI D1870	108-116	IKAROS family zinc finger 3	Homo sapiens	270-275
32637030-3	2020	To examine the role of RSK in AML, we analyzed apoptosis and the cell cycle profile following treatment with BI-D1870, a potent inhibitor of RSK.	BI D1870	109-117	ribosomal protein S6 kinase A2	Homo sapiens	141-144
32637030-6	2020	BI-D1870 treatment impeded the association of activator CDC20 with APC/C, but increased binding of inhibitor MAD2 to CDC20, preventing mitotic exit.	BI D1870	0-8	cell division cycle 20	Homo sapiens	56-61
32637030-6	2020	BI-D1870 treatment impeded the association of activator CDC20 with APC/C, but increased binding of inhibitor MAD2 to CDC20, preventing mitotic exit.	BI D1870	0-8	mitotic arrest deficient 2 like 1	Homo sapiens	109-113
32637030-6	2020	BI-D1870 treatment impeded the association of activator CDC20 with APC/C, but increased binding of inhibitor MAD2 to CDC20, preventing mitotic exit.	BI D1870	0-8	cell division cycle 20	Homo sapiens	117-122
32637030-7	2020	Moreover, the inactivation of spindle assembly checkpoint or MAD2 knockdown released cells from BI-D1870-induced metaphase arrest.	BI D1870	96-104	mitotic arrest deficient 2 like 1	Homo sapiens	61-65
24241211-6	2014	In addition, BI-D1870 also induced G2/M arrest by modulating the expression of p21 and other cell cycle regulators.	BI D1870	13-21	H3 histone pseudogene 16	Homo sapiens	79-82
27040869-5	2016	The combined use of the S6K inhibitor BI-D1870 with TNF-alpha inhibited the PKC-zeta to p47(phox) interaction, inhibited ROS production, degraded PKC-zeta, and activated caspases-3 and -8 to block transformation from blebbishields.	BI D1870	38-46	protein kinase C zeta	Homo sapiens	76-84
27040869-5	2016	The combined use of the S6K inhibitor BI-D1870 with TNF-alpha inhibited the PKC-zeta to p47(phox) interaction, inhibited ROS production, degraded PKC-zeta, and activated caspases-3 and -8 to block transformation from blebbishields.	BI D1870	38-46	pleckstrin	Homo sapiens	88-91
27040869-5	2016	The combined use of the S6K inhibitor BI-D1870 with TNF-alpha inhibited the PKC-zeta to p47(phox) interaction, inhibited ROS production, degraded PKC-zeta, and activated caspases-3 and -8 to block transformation from blebbishields.	BI D1870	38-46	protein kinase C zeta	Homo sapiens	146-187
26386981-3	2016	The pan-RSK inhibitor BI-D1870 also inhibits TH17 differentiation, but the effect of BI-D1870 in vivo remains unclear.	BI D1870	22-30	ribosomal protein S6 kinase polypeptide 1	Mus musculus	8-11
26580203-7	2015	On the other hand, both the EGF-stimulated phosphorylation of T1736 and the EGF-induced dissolution of HDs are dependent on a functional MAPK signaling pathway, and treatment with the RSK inhibitor BI-D1870 prevented EGF-stimulated phosphorylation of beta4-T1736.	BI D1870	198-206	mitogen-activated protein kinase 3	Homo sapiens	137-141
26580203-7	2015	On the other hand, both the EGF-stimulated phosphorylation of T1736 and the EGF-induced dissolution of HDs are dependent on a functional MAPK signaling pathway, and treatment with the RSK inhibitor BI-D1870 prevented EGF-stimulated phosphorylation of beta4-T1736.	BI D1870	198-206	ribosomal protein S6 kinase A1	Homo sapiens	184-187
26580203-7	2015	On the other hand, both the EGF-stimulated phosphorylation of T1736 and the EGF-induced dissolution of HDs are dependent on a functional MAPK signaling pathway, and treatment with the RSK inhibitor BI-D1870 prevented EGF-stimulated phosphorylation of beta4-T1736.	BI D1870	198-206	tubulin beta 3 class III	Homo sapiens	251-256
25889895-0	2015	Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.	BI D1870	32-40	ribosomal protein S6 kinase A2	Homo sapiens	16-19
25889895-0	2015	Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.	BI D1870	32-40	CREB regulated transcription coactivator 1	Mus musculus	59-65
25889895-0	2015	Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.	BI D1870	32-40	ribosomal protein S6 kinase A2	Homo sapiens	81-84
25889895-3	2015	BI-D1870 and SL0101 are two widely used inhibitors of RSK.	BI D1870	0-8	ribosomal protein S6 kinase A2	Homo sapiens	54-57
25889895-14	2015	We thus conclude that SL0101 and BI-D1870 induce distinct off-target effects in mTORC1-p70S6K signaling, and thus, the functions previously ascribed to RSK based on these inhibitors should be reassessed.	BI D1870	33-41	CREB regulated transcription coactivator 1	Mus musculus	80-86
25889895-14	2015	We thus conclude that SL0101 and BI-D1870 induce distinct off-target effects in mTORC1-p70S6K signaling, and thus, the functions previously ascribed to RSK based on these inhibitors should be reassessed.	BI D1870	33-41	ribosomal protein S6 kinase B1	Homo sapiens	87-93
25889895-14	2015	We thus conclude that SL0101 and BI-D1870 induce distinct off-target effects in mTORC1-p70S6K signaling, and thus, the functions previously ascribed to RSK based on these inhibitors should be reassessed.	BI D1870	33-41	ribosomal protein S6 kinase A2	Homo sapiens	152-155
25579842-5	2015	Nodular melanoma cells were more sensitive to RSK1 inhibition using siRNA and the pharmacological inhibitor BI-D1870 compared with superficial spreading cells.	BI D1870	108-116	ribosomal protein S6 kinase A1	Homo sapiens	46-50
24057571-8	2014	Treatment with rapamycin, an mTOR inhibitor, MK2206, an Akt inhibitor, and BI-D1870, a RSK inhibitor, partially suppressed CdCl2-induced ATF4 expression.	BI D1870	75-83	ribosomal protein S6 kinase A3	Homo sapiens	87-90
24057571-8	2014	Treatment with rapamycin, an mTOR inhibitor, MK2206, an Akt inhibitor, and BI-D1870, a RSK inhibitor, partially suppressed CdCl2-induced ATF4 expression.	BI D1870	75-83	activating transcription factor 4	Homo sapiens	137-141
24241211-2	2014	This study aims to investigate the role of BI-D1870, a specific inhibitor of p90 RSKs, in a panel of OSCC cell lines.	BI D1870	43-51	transferrin receptor	Homo sapiens	77-80
27080258-7	2016	FSH-stimulated phosphorylation of YB-1(Ser(102)) is prevented by pretreatment of GCs with the PKA-selective inhibitor PKA inhibitor (PKI), the MEK inhibitor PD98059, or the ribosomal S6 kinase-2 (RSK-2) inhibitor BI-D1870.	BI D1870	213-221	Y-box binding protein 1	Homo sapiens	34-38
27080258-7	2016	FSH-stimulated phosphorylation of YB-1(Ser(102)) is prevented by pretreatment of GCs with the PKA-selective inhibitor PKA inhibitor (PKI), the MEK inhibitor PD98059, or the ribosomal S6 kinase-2 (RSK-2) inhibitor BI-D1870.	BI D1870	213-221	ribosomal protein S6 kinase A3	Homo sapiens	173-194
27049728-7	2016	Similarly, BI-D1870, a specific inhibitor of p90RSK, significantly inhibited the metastatic potential of highly invasive MDA-MB-231 and moderately invasive MDA-MB-468 TNBC cells, but was minimally effective in non-invasive Hs578T TNBC cells.	BI D1870	11-19	ribosomal protein S6 kinase A1	Homo sapiens	45-51
25670857-10	2015	The tPA-mediated macrophage survival was eliminated by PD98059, BI-D1870, or sc68376, the specific inhibitors for Erk1/2, p90RSK, or p38, respectively.	BI D1870	64-72	plasminogen activator, tissue	Mus musculus	4-7
25670857-10	2015	The tPA-mediated macrophage survival was eliminated by PD98059, BI-D1870, or sc68376, the specific inhibitors for Erk1/2, p90RSK, or p38, respectively.	BI D1870	64-72	mitogen-activated protein kinase 3	Mus musculus	114-120
25670857-10	2015	The tPA-mediated macrophage survival was eliminated by PD98059, BI-D1870, or sc68376, the specific inhibitors for Erk1/2, p90RSK, or p38, respectively.	BI D1870	64-72	ribosomal protein S6 kinase polypeptide 1	Mus musculus	122-128
25670857-10	2015	The tPA-mediated macrophage survival was eliminated by PD98059, BI-D1870, or sc68376, the specific inhibitors for Erk1/2, p90RSK, or p38, respectively.	BI D1870	64-72	mitogen-activated protein kinase 14	Mus musculus	133-136
27919044-0	2014	A combination of SILAC and nucleotide acyl phosphate labelling reveals unexpected targets of the Rsk inhibitor BI-D1870.	BI D1870	111-119	ribosomal protein S6 kinase polypeptide 1	Mus musculus	97-100
27919044-5	2014	We confirmed that these kinases, including Slk, Lok and Mst1, are inhibited by BI-D1870 but to a much lesser extent by BIX 02565 and that phosphorylation of some of their substrates is blocked by BI-D1870 in living cells.	BI D1870	79-87	STE20-like kinase	Mus musculus	43-46
27919044-5	2014	We confirmed that these kinases, including Slk, Lok and Mst1, are inhibited by BI-D1870 but to a much lesser extent by BIX 02565 and that phosphorylation of some of their substrates is blocked by BI-D1870 in living cells.	BI D1870	79-87	serine/threonine kinase 10	Mus musculus	48-51
27919044-5	2014	We confirmed that these kinases, including Slk, Lok and Mst1, are inhibited by BI-D1870 but to a much lesser extent by BIX 02565 and that phosphorylation of some of their substrates is blocked by BI-D1870 in living cells.	BI D1870	79-87	macrophage stimulating 1 (hepatocyte growth factor-like)	Mus musculus	56-60
27919044-5	2014	We confirmed that these kinases, including Slk, Lok and Mst1, are inhibited by BI-D1870 but to a much lesser extent by BIX 02565 and that phosphorylation of some of their substrates is blocked by BI-D1870 in living cells.	BI D1870	196-204	STE20-like kinase	Mus musculus	43-46
27919044-5	2014	We confirmed that these kinases, including Slk, Lok and Mst1, are inhibited by BI-D1870 but to a much lesser extent by BIX 02565 and that phosphorylation of some of their substrates is blocked by BI-D1870 in living cells.	BI D1870	196-204	serine/threonine kinase 10	Mus musculus	48-51
27919044-5	2014	We confirmed that these kinases, including Slk, Lok and Mst1, are inhibited by BI-D1870 but to a much lesser extent by BIX 02565 and that phosphorylation of some of their substrates is blocked by BI-D1870 in living cells.	BI D1870	196-204	macrophage stimulating 1 (hepatocyte growth factor-like)	Mus musculus	56-60
24403857-9	2013	Genetic as well as pharmacological inhibition of RPS6KA2 by the inhibitor BI-D1870 acted synergistically with erlotinib.	BI D1870	74-82	ribosomal protein S6 kinase A2	Homo sapiens	49-56
23940083-14	2014	Inhibiting RSK with siRNA or BI-D1870 suppressed growth, induced apoptosis, and sensitized cells to SHH agents.	BI D1870	29-37	sonic hedgehog signaling molecule	Homo sapiens	100-103
23516539-6	2013	During both Ca(2+)- and agonist (U46619) induced SM contraction, RSK inhibition by the highly selective compound BI-D1870 (which has no effect on MLCK or ROCK) resulted in significant suppression of contractile force.	BI D1870	113-121	ribosomal protein S6 kinase A2	Homo sapiens	65-68
24136223-0	2013	The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1.	BI D1870	44-52	ribosomal protein S6 kinase A1	Homo sapiens	29-32
24136223-0	2013	The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1.	BI D1870	44-52	ribosomal protein S6 kinase A1	Homo sapiens	126-129
24136223-0	2013	The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1.	BI D1870	44-52	tumor protein p53	Homo sapiens	135-138
24136223-0	2013	The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1.	BI D1870	44-52	cyclin dependent kinase inhibitor 1A	Homo sapiens	175-179
24136223-3	2013	Here, we report that BI-D1870, a potent small molecule inhibitor of RSKs, induces apoptosis, although preferentially, in a p21-deficient background.	BI D1870	21-29	cyclin dependent kinase inhibitor 1A	Homo sapiens	123-126
24136223-5	2013	Although we identified p21 in in vitro kinase assays as a novel RSK substrate that specifically becomes phosphorylated by RSK1-3 at Ser116 and Ser146, RNA-interference, overexpression and co-immunoprecipitation studies as well as the use of SL0101, another specific RSK inhibitor, revealed that BI-D1870 mediates p21 accumulation via a yet unknown pathway that, besides its off-site targets polo-like kinase-1 and AuroraB, also does also not involve RSKs.	BI D1870	295-303	cyclin dependent kinase inhibitor 1A	Homo sapiens	23-26
24136223-5	2013	Although we identified p21 in in vitro kinase assays as a novel RSK substrate that specifically becomes phosphorylated by RSK1-3 at Ser116 and Ser146, RNA-interference, overexpression and co-immunoprecipitation studies as well as the use of SL0101, another specific RSK inhibitor, revealed that BI-D1870 mediates p21 accumulation via a yet unknown pathway that, besides its off-site targets polo-like kinase-1 and AuroraB, also does also not involve RSKs.	BI D1870	295-303	ribosomal protein S6 kinase A1	Homo sapiens	64-67
24136223-5	2013	Although we identified p21 in in vitro kinase assays as a novel RSK substrate that specifically becomes phosphorylated by RSK1-3 at Ser116 and Ser146, RNA-interference, overexpression and co-immunoprecipitation studies as well as the use of SL0101, another specific RSK inhibitor, revealed that BI-D1870 mediates p21 accumulation via a yet unknown pathway that, besides its off-site targets polo-like kinase-1 and AuroraB, also does also not involve RSKs.	BI D1870	295-303	ribosomal protein S6 kinase A1	Homo sapiens	122-126
24136223-5	2013	Although we identified p21 in in vitro kinase assays as a novel RSK substrate that specifically becomes phosphorylated by RSK1-3 at Ser116 and Ser146, RNA-interference, overexpression and co-immunoprecipitation studies as well as the use of SL0101, another specific RSK inhibitor, revealed that BI-D1870 mediates p21 accumulation via a yet unknown pathway that, besides its off-site targets polo-like kinase-1 and AuroraB, also does also not involve RSKs.	BI D1870	295-303	ribosomal protein S6 kinase A1	Homo sapiens	122-125
23510923-9	2013	Furthermore, BI-D1870, an inhibitor of the p90(RSK)s, protein kinases which are activated by ERK, blocks PE-activated rRNA synthesis, as did a second p90(RSK) inhibitor, SL0101.	BI D1870	13-21	transferrin receptor	Homo sapiens	43-46
23510923-9	2013	Furthermore, BI-D1870, an inhibitor of the p90(RSK)s, protein kinases which are activated by ERK, blocks PE-activated rRNA synthesis, as did a second p90(RSK) inhibitor, SL0101.	BI D1870	13-21	ribosomal protein S6 kinase A2	Homo sapiens	47-50
23510923-9	2013	Furthermore, BI-D1870, an inhibitor of the p90(RSK)s, protein kinases which are activated by ERK, blocks PE-activated rRNA synthesis, as did a second p90(RSK) inhibitor, SL0101.	BI D1870	13-21	mitogen-activated protein kinase 1	Homo sapiens	93-96
23510923-9	2013	Furthermore, BI-D1870, an inhibitor of the p90(RSK)s, protein kinases which are activated by ERK, blocks PE-activated rRNA synthesis, as did a second p90(RSK) inhibitor, SL0101.	BI D1870	13-21	transferrin receptor	Homo sapiens	150-153
23510923-9	2013	Furthermore, BI-D1870, an inhibitor of the p90(RSK)s, protein kinases which are activated by ERK, blocks PE-activated rRNA synthesis, as did a second p90(RSK) inhibitor, SL0101.	BI D1870	13-21	ribosomal protein S6 kinase A2	Homo sapiens	154-157
23215897-12	2013	PD184352 or BI-D1870 prevented the increased surface area induced by endothelin-1 in cardiomyocytes.	BI D1870	12-20	endothelin 1	Rattus norvegicus	69-81
24303063-6	2013	In addition, MEK inhibitors and the RSK-inhibitor BI-D1870 interfere in mTORC1 activity, suggesting that RSK acts as a bypass for Rheb in activating mTORC1.	BI D1870	50-58	ribosomal protein S6 kinase polypeptide 1	Mus musculus	36-39
24303063-6	2013	In addition, MEK inhibitors and the RSK-inhibitor BI-D1870 interfere in mTORC1 activity, suggesting that RSK acts as a bypass for Rheb in activating mTORC1.	BI D1870	50-58	CREB regulated transcription coactivator 1	Mus musculus	72-78
24303063-6	2013	In addition, MEK inhibitors and the RSK-inhibitor BI-D1870 interfere in mTORC1 activity, suggesting that RSK acts as a bypass for Rheb in activating mTORC1.	BI D1870	50-58	ribosomal protein S6 kinase polypeptide 1	Mus musculus	105-108
24303063-6	2013	In addition, MEK inhibitors and the RSK-inhibitor BI-D1870 interfere in mTORC1 activity, suggesting that RSK acts as a bypass for Rheb in activating mTORC1.	BI D1870	50-58	Ras homolog enriched in brain	Mus musculus	130-134
24303063-6	2013	In addition, MEK inhibitors and the RSK-inhibitor BI-D1870 interfere in mTORC1 activity, suggesting that RSK acts as a bypass for Rheb in activating mTORC1.	BI D1870	50-58	CREB regulated transcription coactivator 1	Mus musculus	149-155
24036112-7	2013	Inhibition of RSK using either the pharmacological inhibitor BI-D1870 or after adenoviral expression of a dominant negative RSK1 mutant (RSK1-DN) showed that RSK selectively phosphorylates IRS-1 on Ser-1101.	BI D1870	61-69	ribosomal protein S6 kinase A1	Rattus norvegicus	124-128
24036112-7	2013	Inhibition of RSK using either the pharmacological inhibitor BI-D1870 or after adenoviral expression of a dominant negative RSK1 mutant (RSK1-DN) showed that RSK selectively phosphorylates IRS-1 on Ser-1101.	BI D1870	61-69	insulin receptor substrate 1	Rattus norvegicus	189-194
23516539-6	2013	During both Ca(2+)- and agonist (U46619) induced SM contraction, RSK inhibition by the highly selective compound BI-D1870 (which has no effect on MLCK or ROCK) resulted in significant suppression of contractile force.	BI D1870	113-121	myosin light chain kinase	Homo sapiens	146-150
21344389-8	2011	We found that the MEK inhibitor U0126 and the RSK inhibitor BI-D1870 both reduced IL-1B-dependent MMP-1 gene expression in SW1353 cells.	BI D1870	60-68	ribosomal protein S6 kinase A2	Homo sapiens	46-49
22674792-5	2012	Despite enrichment for TICs, these cells were sensitive to RSK inhibition when treated ex vivo with BI-D1870.	BI D1870	100-108	ribosomal protein S6 kinase A3	Homo sapiens	59-62
21344389-8	2011	We found that the MEK inhibitor U0126 and the RSK inhibitor BI-D1870 both reduced IL-1B-dependent MMP-1 gene expression in SW1353 cells.	BI D1870	60-68	interleukin 1 beta	Homo sapiens	82-87
21344389-8	2011	We found that the MEK inhibitor U0126 and the RSK inhibitor BI-D1870 both reduced IL-1B-dependent MMP-1 gene expression in SW1353 cells.	BI D1870	60-68	matrix metallopeptidase 1	Homo sapiens	98-103
21501342-6	2011	The RSK inhibitor BI-D1870 suppressed SH3P2 phosphorylation and tumor cell motility as effectively as did the MEK inhibitor PD184352.	BI D1870	18-26	ribosomal protein S6 kinase polypeptide 1	Mus musculus	4-7
21501342-6	2011	The RSK inhibitor BI-D1870 suppressed SH3P2 phosphorylation and tumor cell motility as effectively as did the MEK inhibitor PD184352.	BI D1870	18-26	osteoclast stimulating factor 1	Mus musculus	38-43